Research Alliance III IPO
Research Alliance III is a stock-only SPAC (Special Purpose Acquisition Company) designed to merge with a private company and take it public. Unlike traditional SPACs that raise cash, stock-only SPACs use their publicly traded shares as currency for acquisitions. Investors are interested in learning which target company Research Alliance III will ultimately merge with.
Key Facts
| Industry | Special Purpose Acquisition Company |
| Funding | $75 million IPO completed in May 2026 |
About Research Alliance III
Research Alliance III is structured as a stock-only SPAC, which represents an evolution of the special purpose acquisition company model that became highly popular in 2020-2021. SPACs are shell companies that go public with the express purpose of merging with a private company, effectively taking that company public through the merger process.
The stock-only structure distinguishes Research Alliance III from traditional SPACs. Rather than raising cash to hold in trust, this vehicle issues publicly traded shares that become the currency for acquiring a target company. This can reduce dilution for target company shareholders and eliminate the pressure to deploy cash within a specific timeframe.
The ultimate success of Research Alliance III will depend on the quality of the target company it identifies and merges with. SPAC sponsors typically have expertise in specific industries or sectors and leverage their networks and experience to find attractive merger candidates. Investors in the SPAC will have the opportunity to vote on any proposed merger and can typically redeem their shares if they don't approve of the selected target.
IPO Status
Research Alliance III is a stock-only SPAC that successfully completed its initial public offering in May 2026, pricing a $75 million IPO. The SPAC is backed by RA Capital, a healthcare-focused investment firm. While conventional SPACs raise capital through an IPO and hold it in trust to fund an acquisition, stock-only SPACs issue shares that serve as the consideration for merging with a target company. This structure can be advantageous for target companies that don't need immediate cash infusion but want access to public markets and the liquidity that comes with being publicly traded. The SPAC sponsor typically identifies and negotiates with potential merger targets within a specified timeframe, usually 18-24 months. No specific target company has been publicly announced for Research Alliance III at this time, though given RA Capital's background, the focus is expected to be in the biotech and biopharma sectors.
Competitors
Frequently Asked Questions
Does Research Alliance III have a stock?
Research Alliance III has not yet completed its IPO or merger transaction. As a stock-only SPAC, it will need to go public and then identify and merge with a target company before investors can participate. Sign up for alerts to stay informed.
When is the Research Alliance III IPO date?
No specific IPO date has been announced for Research Alliance III. The timeline will depend on market conditions and the SPAC's readiness to file with the SEC and begin trading. Sign up for alerts to stay informed.
How can I buy Research Alliance III stock?
Research Alliance III shares are not currently available for purchase. Once the SPAC completes its public offering, shares will be tradeable through standard brokerage accounts, and investors can participate in the eventual merger transaction. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts